Treatment
Tacrolimus clinical trials
We’re tracking 79 recruiting studies that include Tacrolimus, each written for real people, not researchers, below.
Recruiting studies
- NCT06354179RecruitingPhase 4
Once-daily immunosuppression after liver transplant
This study tests whether taking immunosuppressive drugs (tacrolimus and mycophenolate mofetil) just once a day, instead of twice, works as well for people who recently had a liver transplant. The goal is to make the medication schedule easier and possibly safer.
BesançonAges 18 years+ - NCT05089604RecruitingPhase 4
Compare two tacrolimus forms to reduce tremors after liver transplant
This study compares immediate-release versus extended-release tacrolimus (an anti-rejection medicine) to see if one form causes fewer tremors after a first liver transplant. It may help you and your care team choose the best form if tremors are a problem while your body adjusts after transplant.
Vancouver, British ColumbiaAges 18 years+ - NCT06591884RecruitingPhase 1/Phase 2
Spray vs ointment for oral lichen planus
This trial tests a new spray version of the medication tacrolimus (enclosed in tiny particles) compared to a standard ointment for treating painful mouth sores caused by oral lichen planus. It aims to see if the spray works better and is easier to use.
Porto Alegre, Rio Grande do SulAges 18 years+ - NCT07302776RecruitingPhase 1
Stopping immune suppression after stem cell transplant
This trial tests whether it's safe to stop one type of anti-rejection medication (tacrolimus) earlier than usual after a stem cell transplant from a matched donor. If you qualify, you may be able to reduce your long-term medication burden.
Palo Alto, CaliforniaAges 18–80 - NCT06268769RecruitingPhase 4
Comparing two tacrolimus drugs in kidney transplant patients
This study compares two long-acting forms of tacrolimus (Envarsus and Advagraf) to see how the body processes them after a kidney transplant. It aims to find the best way to use these medications to prevent organ rejection.
AachenAges 18 years+ - NCT04469842RecruitingEarly Phase 1
Long-acting tacrolimus after lung transplant
This early-stage study tests a long-acting form of tacrolimus (a common anti-rejection medicine) soon after lung transplant. It aims to see if it can be used safely and effectively for people receiving lung transplants at Vanderbilt (VUMC).
Nashville, TennesseeAges 18 years+ - NCT06751992RecruitingPhase 4
Thinking and memory with extended-release tacrolimus in kidney transplant
This study tests if switching to an extended-release form of your anti-rejection medication (tacrolimus) helps protect memory and thinking skills. It is for older adults who have had a kidney transplant at least one year ago.
Boston, MassachusettsAges 65 years+ - NCT06880042Enrolling by invitationEarly Phase 1
Narrowband UVB light therapy with tacrolimus or calcipotriol for vitiligo
This study compares two treatments for vitiligo: narrowband UVB light therapy combined with either tacrolimus ointment or calcipotriol ointment. It aims to see which combination works better and is safer for people with stable, limited vitiligo.
Lahore, Punjab ProvinceAges 15–70 - NCT06235892RecruitingPhase 3
Lowering Tacrolimus for Low-Risk Kidney Transplant Patients
This trial tests whether safely lowering the dose of tacrolimus—an anti-rejection drug—can still protect a kidney transplant one year after surgery. It's for first-time transplant recipients with low immune risk.
NantesAges 18 years+ - NCT05252754RecruitingPhase 3
Medicines to prevent pancreas swelling after ERCP
This Phase 3 study tests whether putting an anti-inflammatory medicine into the rectum (indomethacin) plus taking an immune-suppressing pill (tacrolimus) works better than using the two medicines in a different combination to prevent pancreatitis after an ERCP procedure. If you qualify, you may be assigned to one of the treatment options to lower your risk of post-ERCP pancreas inflammation.
Baltimore, MarylandAges 18 years+ - NCT06529536RecruitingPhase 4
Personalized tacrolimus dosing for children after transplant
This trial tests a new way to personalize tacrolimus dosing for children after a kidney, liver, or heart transplant. It uses genetic information and a formula to find the best starting dose, aiming to improve outcomes.
Melbourne, VictoriaAges 1–18 - NCT06280950RecruitingPhase 2
Reducing immune-suppressing drugs after liver transplant with everolimus
This study tests if adding everolimus can allow liver transplant recipients to safely reduce their usual immune-suppressing medicines. It aims to protect kidney function while preventing organ rejection.
Phoenix, ArizonaAges 18 years+ - NCT07412470RecruitingPhase 2/Phase 3
Testing frexalimab vs tacrolimus for new kidney transplant patients
This trial compares a new drug called frexalimab to the standard drug tacrolimus in people who are getting their first kidney transplant. The goal is to see if frexalimab works better and has a safer side effect profile.
Boston, MassachusettsAges 18–70 - NCT06055608RecruitingPhase 2
Improving kidney transplant outcomes in teens and young adults
This trial tests a new approach to help teenagers and young adults keep their first kidney transplant working well. It looks at how to improve long-term success by carefully managing the immune system around the time of transplant.
Birmingham, AlabamaAges 13–20 - NCT06833463Recruiting
Tacrolimus and diabetes risk in kidney transplant patients
This study looks at how the anti-rejection drug tacrolimus (specifically Envarsus) affects blood sugar and risk of diabetes in kidney transplant patients. It aims to find out which patients might be more likely to develop glucose problems so doctors can adjust treatment early.
GdanskAges 18 years+ - NCT07285070RecruitingPhase 2
Tacrolimus eye drops for non-infectious anterior uveitis
This trial tests a new eye drop (tacrolimus) to treat non-infectious anterior uveitis, an inflammation in the front part of the eye. It may help reduce the need for steroid eye drops.
Phoenix, ArizonaAges 18 years+ - NCT06183892Recruiting
Extended-release tacrolimus in stable child liver transplant recipients
This study tests an extended-release version of the anti-rejection drug tacrolimus in children who have already had a stable liver transplant. The goal is to see if the longer-acting capsule works as well as the immediate-release form, potentially simplifying daily medication routines.
ShanghaiAges 6 months–18 years - NCT05744635Recruiting
Study tacrolimus levels after liver transplant
This non-interventional study looks at how tacrolimus blood levels relate to transplant effectiveness and side effects. It uses your existing medical data to understand whether tacrolimus behaves differently from person to person and how that links to safety.
BudapestAges 18 years+ - NCT05916781RecruitingPhase 4
Lowering steroids with mycophenolate and tacrolimus for lupus kidneys
This study tests whether using mycophenolate mofetil plus tacrolimus can help people with lupus nephritis safely lower (taper) their prednisone to a low dose. It is designed for people whose kidney lupus has been well-controlled for at least 6 months.
BeijingAges 18–65 - NCT06128070RecruitingPhase 2
Preventing GVHD after stem cell transplant for leukemia
This trial tests adding ruxolitinib to standard drugs (tacrolimus and methotrexate) to prevent graft-versus-host disease in children and young adults undergoing a stem cell transplant for acute leukemia or myelodysplastic syndrome. The goal is to lower the risk of GVHD and improve transplant outcomes.
Duarte, CaliforniaAges 2–22 - NCT06701825RecruitingPhase 4
Genetic testing before tacrolimus in kidney transplant
This study tests whether doing a simple genetic test before starting the anti-rejection drug tacrolimus can lead to better dosing and outcomes in kidney transplant patients. It also looks at whether this approach is cost-effective.
Madrid, MadridAges Any age - NCT06815003RecruitingPhase 2
Preventing Graft-Versus-Host Disease After Stem Cell Transplant
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
Duarte, CaliforniaAges 18–80 - NCT06828796RecruitingPhase 2
Early tacrolimus with half-matched stem cell transplant for blood cancer
This trial tests whether giving tacrolimus early after a half-matched donor stem cell transplant can improve outcomes for patients with blood cancer. The donor must be a family member who shares about half of your HLA markers.
Atlanta, GeorgiaAges 18–80 - NCT06900777Recruiting
Comparing two treatments for rapidly spreading vitiligo in children
This trial compares two medicines—oral tacrolimus and dexamethasone micro-pulse therapy—in children aged 4 to 12 whose vitiligo is spreading quickly. The goal is to see which treatment works better to stop the spread and help color return to the skin.
Xi'an, ShaanxiAges 4–12
What Tacrolimus is being studied for
Conditions with recruiting Tacrolimus studies.
Common questions
- Are there clinical trials studying Tacrolimus?
- Yes. Clin2 currently lists 79 recruiting studies that include Tacrolimus, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Tacrolimus trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Tacrolimus an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Tacrolimus or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.